In the BioHarmony Drug Report Database
Durvalumab
Imfinzi (durvalumab) is an antibody pharmaceutical. Durvalumab was first approved as Imfinzi on 2017-05-01. It is used to treat transitional cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against programmed cell death 1 ligand 1.
Trade Name
|
Imfinzi |
|---|---|
Common Name
|
durvalumab |
ChEMBL ID
|
CHEMBL3301587 |
Indication
|
non-small-cell lung carcinoma, transitional cell carcinoma |
Drug Class
|
Monoclonal antibodies: fully human, immunomodulating |
Image (chem structure or protein)
